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We present the case of a 13-year-old patient who underwent right salpingo-oophorectomy and was
diagnosed with stage Ia ovarian mucinous cystadenocarcinoma. Nine years after complete resection, she
was diagnosed with metastasis of the previously resected carcinoma. Despite receiving combination
chemotherapy, the patient died of the disease. Long-term follow-up of teenage patients with stage Ia
ovarian mucinous cystadenocarcinoma is important.
Crown Copyright  2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license. Epithelial ovarian carcinoma (EOC) is the leading cause of death
due to gynecological malignancies [1]. The standard surgical treat-
ment for patients with EOC involves hysterectomy and bilateral
salpingo-oophorectomy with peritoneal sampling (peritoneal
washing, omentectomy, multiple peritoneal biopsies, and perito-
neal implant removal), with or without lymph node sampling [2].
Several reports have estimated that 3%e17% of all EOCs develop in
women under 40 years of age and that the incidence of this con-
dition in teenage patients is rare [3]. Current studies on patients
with stage I EOC suggest a comparatively more favorable prognosis
on treatment with FSS compared radical surgery [2e6]. It has also
been shown that the long-term outcome of patients with stage Ia
mucinous carcinomas with no apparent disease in the peritoneum
is favorable [7]. Herein, we report the case of a teenage girl with late
recurrence who was previously treated for stage Ia ovarian
mucinous cystadenocarcinoma. We also performed a literature
review of case reports describing recurrence after tumor resection
in teenagers with stage Ia EOC.1. Case report
A 13-year-old girl was referred to our hospital because of
abdominal distension. Her family history was unremarkable.c Association’s 43rd Annual
; fax: þ81 3 3554 1321.
. Sugito).
vier Inc. Open access under CC BY-NCPhysical examination and subsequent abdominal ultrasonography
and computed tomography (CT) conﬁrmed the presence of a very
large solid cystic mass in the lower abdomen (Fig. 1). Serum levels
of carcinoembryonic antigen (CEA, 16.2 ng/mL; normal range,
below 10 ng/mL), carbohydrate antigen 19-9 (CA19-9, 2249.0 U/mL;
normal range, below 37 U/mL), and carbohydrate antigen 125
(CA125, 49.9 U/mL; normal range, below 40 U/mL) were consider-
ably elevated. The patient underwent right salpingo-oophorectomy,
and a right ovarian tumor was diagnosed. Visualization and
palpation did not reveal disease. Wedge resection of the remaining
ovary was not performed. Pathological examination of the right
ovary revealed multiloculated cysts lined by tall mucin-secreting
columnar epithelial cells. In addition, at places with epithelium
stratiﬁcation, papillary and cribriform patterns were observed. The
pathological ﬁndings of the washings were negative. International
Federation of Gynecology and Obstetrics stage Ia (T1aN0M0), grade
1 ovarian mucinous cystadenocarcinoma was diagnosed. After
surgery, the levels of each tumor marker returned to normal within
3 weeks. The patient was discharged from the hospital after expe-
riencing complete remission, and she was followed closely without
adjuvant therapy.
Tumor marker levels were examined twice every year. Serum
levels of CEA, CA19-9, and CA125 were low during the ﬁrst 7 years
after the operation. Nine years after complete tumor resection
(21 years old, gravida 0, para 0), the patient complained of respira-
tory discomfort. Chest radiography and CT conﬁrmed the presence
of multiple coin lesions in the bilateral lung ﬁelds. Laboratory
investigation of tumor marker levels (CEA, 24.6 ng/mL; CA19-9,-ND license. 
Fig. 1. Computed tomography (CT) scans conﬁrmed the presence of a very large solid
cystic mass in the lower abdomen.
T. Masuko et al. / J Ped Surg Case Reports 1 (2013) 174e176 1759860.0 U/mL; and CA125, 245.8 U/mL) revealed that they were
elevated. Bronchoscopy revealed that the superior segment was
incompletely occluded by angiectasis and adenomatous hyperplastic
epithelium. Transbronchial lung biopsy revealed atypical gland for-
mation the lung tissue, including in the alveoli. Expression of thyroid
transcription factor-1 was negative. The biopsy ﬁndings suggested
that metastasis of the previously resected ovarian mucinous cys-
tadenocarcinoma had occurred. Fluorine-18 ﬂuorodeoxyglucose
positron emission tomography/CT revealed metastasis to the left
lung, pulmonary hilum, left buccal region, liver, mediastinal space,
pelvic space, bilateral arms, and subcutaneous layers. Bone scintig-
raphy revealed hot lesions at the pelvic bone, bilateral femoral bone,
skull bone, spine, and costal bone. Recurrent ovarian mucinous
cystadenocarcinoma was diagnosed, and the patient was treated
with carboplatin and paclitaxel combination chemotherapy. The
chemotherapy regimen comprised of 794 mg carboplatin (area un-
der the curve of 4.5) and 237 mg paclitaxel (170 mg/m2). Despite the
combination chemotherapy treatment, levels of each tumor markerTable 1
Case reports of recurrence after tumor resection for stage Ia epithelial ovarian carcinom
Ref. Age at
diagnosis
(years)
Histology Grade Size
of the
tumor
(cm)
Rupture Surgical
procedure
Adjuvan
chemot
Satoh et al. [8] 18 Muc 1 NA NA USO No
19 Muc 1 NA NA USO No
Park et al. [9] 15 Muc NA 50 No USO No
15 Muc NA 30 No USO No
Morice
et al. [2]
18 Muc 1 NA NA USO No
16 Muc 2 NA NA USO No
Schilder
et al. [10]
19 Muc 2 NA NA USO No
Present case 14 Muc 1 40 No USO No
EOC, epithelial ovarian carcinoma; Muc, mucinous cystadenocarcinoma; USO, unilateral s
of disease; DOD, died of disease; NA, not available.increased, and the patient died of the disease 5 months after the
diagnosis of recurrence.
2. Discussion
The key to feritility-sparing surgery (FSS) is to have adequate
information about the biology and stage of the cancer. FSS for pa-
tients of reproductive age with invasive EOC has been adopted for
stage Ia tumors according to the 2007 guidelines of the American
College of Obstetrics and Gynecology [8] and for unilateral stage I
tumors without dense adhesions and with favorable histology
according to the 2008 guidelines of the European Society for
Medical Oncology [9]. In Japan, FSS has been recommended for
patients with stage Ia tumors [10].
Characteristics of recurrence after FSS for stage Ia EOC in
teenagers as described in the literature are shown in Table 1
[2,4e6]. Recurrence after tumor resection has been described in
8 of these patients, including the patient described here (Table 1).
The age of the patients at the initial diagnosis ranged from 14 to 19
years (average age, 16.8 years). The histological ﬁndings of these
cases indicated low-grade mucinous cystadenocarcinoma. The size
of the primary tumor could be determined for 3 of the 8 patients
and ranged from 30 to 50 cm (median, 40 cm). None of the 8 pa-
tients received adjuvant chemotherapy. Of the 8 patients, 4 had
relapses involving the remaining ovary and 3 had relapses
involving the lungs. No patients died of local recurrence. The
recurrence-free interval was 2e118 months (median, 74 months).
Four of 6 patients died of diseasewithin 5 years of recurrence being
diagnosed. In the treatment of recurrence, salvage surgery of
contralateral salpingo-oophorectomy may not be effective, and
distant recurrence sites were refractory to chemotherapy. Recur-
rence occurs late and is systemic in teenage patients with stage Ia
EOC. Cases of large mucinous cystadenocarcinomas in teenagers
are characterized by a poor prognosis. Chan et al. [11] reported that
age, stage, grade, and cytology are important prognostic factors for
high-risk early-stage EOC. Although these data are based on a very
small amount of retrospective data, the strategy of surgical treat-
ment and adjuvant therapy chosen are important for teenage pa-
tients with early-stage EOC. After surgical resection, selecting a
treatment strategy based on the biology of each individual’s tumor
is also important.
Adjuvant chemotherapy is associated with improved recurrence-
free survival in patients with early-stage ovarian cancer witha in teenage patients.
t
herapy
Site of
recurrence
Recurrence-free
interval
(months)
Treatment for
recurrence
Follow-up
interval after
recurrence
(months)
Status
Remaining
ovary
83 Salvage surgery 119 NED
Peritoneum 70 NA 149 NED
Remaining
ovary
41 Ovarian
cystectomy
NA NED
Lung,
pericardium
82 Biopsy NA DOD
Remaining
ovary
7 Surgery, ChT 40 DOD
Remaining
ovary
2 Surgery 54 DOD
Lung 78 RT, ChT 19 DOD
Lungs, bones 118 ChT 5 DOD
alpingo-oophorectomy; ChT, chemotherapy; RT, radiation therapy; NED, no evidence
T. Masuko et al. / J Ped Surg Case Reports 1 (2013) 174e176176nonoptimal staging [12]. However, in teenage patients with recur-
rent early-stage EOC treated with unilateral salpingo-oophorectomy
without adjuvant therapy, long-term prognosis is not as favorable as
that described in adult patients. This is true even for patients with
stage Ia tumors [2e6]. We should be aware of the possibility of
recurrence in teenage patients with primary large mucinous
cystadenocarcinoma.
3. Conclusion
Herein, we report a case of late recurrence in a teenage
girl previously treated for stage Ia ovarian mucinous cys-
tadenocarcinoma. Long-term follow-up of teenage patients
with stage Ia ovarian mucinous cystadenocarcinoma is therefore
important.
Conﬂicts of interest
The authors have no conﬂicts of interest to report.
Sources of funding
The authors have no source(s) of funding to report or
acknowledge.
References
[1] Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA
Cancer J Clin 2001;51:15e36.[2] Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, et al. Conservative
treatment in epithelial ovarian cancer: results of a multicentre study of the
GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG
(Societe Francaise d’Oncologie Gynecologique). Hum Reprod 2005;20:1379e85.
[3] Kajiyama H, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, et al. Fertility-
sparing surgery in young women with invasive epithelial ovarian cancer. EJSO
2010;36:404e8.
[4] American College of Obstetricians and Gynecologists. ACOG Practice
Bulletin: management of adnexal masses. Obstet Gynecol 2007;110:
201e14.
[5] Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO clinical recom-
mendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19:
ii14e6.
[6] Japan Society of Gynecologic Oncology. Ovarian cancer treatment guidelines
2007. Tokyo, Japan: Kanehara; 2007. pp. 33e35. [in Japanese].
[7] Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor
type and substage predict survival in stage I and II ovarian carcinoma: insights
and implications. Gynecol Oncol 2010;116:50e6.
[8] Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes
of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for
patient selection. J Clin Oncol 2010;28:1727e32.
[9] Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Surgical management of
borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol
2009;113:75e82.
[10] Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al.
Outcome of reproductive age women with stage IA or IC invasive epithelial
ovarian cancer treatedwith fertility-sparing therapy. Gynecol Oncol 2002;87:1e7.
[11] Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for
high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group
study. Cancer 2008;112:2202e10.
[12] Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al.
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian
carcinoma: European Organization for Research and Treatment of Cancer-
Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;
95:113e25.
